

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **SYS6037 INJECTION (MPOX MRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYS6037 Injection (mpox mRNA Vaccine) (the “**Product**”), a Class 1 new drug for preventive biological products co-developed by the Group and the Institute of Microbiology, the Chinese Academy of Sciences, has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.

Mpox is caused by the mpox virus, which belongs to the *Orthopoxvirus* genus of the *Poxviridae* family. The Product is a multi-antigen mpox vaccine encoded by a single mRNA strand for the prevention of mpox. Its simplified technical route facilitates quality control in the production process and can significantly reduce production costs, thereby enhancing the controllability and accessibility of the vaccine.

Pre-clinical studies demonstrated that, compared with the live-attenuated vaccine (Tiantan strain), the Product exhibited superior immunogenicity and protective efficacy, and displayed broad-spectrum cross-reactivity against various *Orthopoxvirus* antigens. The Product is expected to become a market-competitive mpox vaccine, further enriching the Group’s innovative mRNA vaccine product pipeline.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 10 August 2026

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*